• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Roxadustat in the treatment of a hemodialysis patient with anti-erythropoietin antibody-mediated pure red cell aplasia.

作者信息

Xu Bojun, Liu Suying, Li Yan, Zhao Liangbin, Song Xinyao, Chen Tong

机构信息

Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.

出版信息

Clin Kidney J. 2021 Jul 10;14(11):2444-2445. doi: 10.1093/ckj/sfab134. eCollection 2021 Nov.

DOI:10.1093/ckj/sfab134
PMID:34754441
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8573001/
Abstract
摘要

相似文献

1
Roxadustat in the treatment of a hemodialysis patient with anti-erythropoietin antibody-mediated pure red cell aplasia.罗沙司他治疗1例抗促红细胞生成素抗体介导的纯红细胞再生障碍性贫血血液透析患者
Clin Kidney J. 2021 Jul 10;14(11):2444-2445. doi: 10.1093/ckj/sfab134. eCollection 2021 Nov.
2
Correction to: Remarkable response to roxadustat in a case of anti-erythropoietin antibody-mediated pure red cell aplasia.
Ann Hematol. 2021 Jan;100(1):305. doi: 10.1007/s00277-020-04300-2.
3
Pure red cell aplasia due to antibody against erythropoietin in hemodialysis patients.血液透析患者中因抗促红细胞生成素抗体导致的纯红细胞再生障碍。
J Nephropathol. 2017 Jan;6(1):25-29. doi: 10.15171/jnp.2017.05. Epub 2016 Aug 22.
4
Prevalence of anti-erythropoietin antibodies in hemodialysis patients without clinical signs of pure red cell aplasia. Comparison between hypo- and normoresponsive patients treated with epoetins for renal anemia.无纯红细胞再生障碍性贫血临床症状的血液透析患者中抗促红细胞生成素抗体的患病率。接受促红细胞生成素治疗肾性贫血的低反应性和正常反应性患者的比较。
Nephron Clin Pract. 2007;105(2):c90-8. doi: 10.1159/000097889. Epub 2006 Dec 12.
5
Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study.促红细胞生成素诱导的纯红细胞再生障碍性贫血的治疗：一项回顾性研究。
Lancet. 2004 May 29;363(9423):1768-71. doi: 10.1016/S0140-6736(04)16302-2.
6
Anti-Erythropoietin Antibody Associated Pure Red Cell Aplasia Resolved after Liver Transplantation.抗促红细胞生成素抗体相关的纯红细胞再生障碍在肝移植后得到缓解。
Case Rep Transplant. 2015;2015:286276. doi: 10.1155/2015/286276. Epub 2015 Jul 9.
7
Successful treatment of anti-erythropoietin antibody-mediated pure red cell aplasia with low-dose prednisolone.低剂量泼尼松龙治疗抗促红细胞生成素抗体介导的纯红细胞再生障碍有效。
Int J Hematol. 2013 Feb;97(2):272-4. doi: 10.1007/s12185-013-1258-3. Epub 2013 Jan 26.
8
Erythropoietin-induced, antibody-mediated pure red cell aplasia.促红细胞生成素诱导的、抗体介导的纯红细胞再生障碍性贫血。
Eur J Clin Invest. 2005 Dec;35 Suppl 3:95-9. doi: 10.1111/j.1365-2362.2005.01536.x.
9
[Diagnosis and management of pure red cell aplasia].[纯红细胞再生障碍性贫血的诊断与管理]
Rinsho Ketsueki. 2021;62(8):931-937. doi: 10.11406/rinketsu.62.931.
10
Pure red-cell aplasia and epoetin therapy.纯红细胞再生障碍性贫血与促红细胞生成素治疗
N Engl J Med. 2004 Sep 30;351(14):1403-8. doi: 10.1056/NEJMoa040528.

引用本文的文献

1
Ziltivekimab for anemia and atherosclerosis in chronic kidney disease: a new hope?泽替夫单抗用于慢性肾脏病贫血和动脉粥样硬化：新希望？
J Nephrol. 2025 Mar;38(2):403-414. doi: 10.1007/s40620-024-02117-0. Epub 2024 Oct 25.
2
Outcomes and complications of hemodialysis in patients with renal cancer following bilateral nephrectomy.双侧肾切除术后肾癌患者的血液透析结局及并发症
Open Med (Wars). 2024 Aug 23;19(1):20241009. doi: 10.1515/med-2024-1009. eCollection 2024.
3
Positive response of a hemodialysis patient with pure red cell aplasia on recombinant human erythropoietin therapy to cyclosporine and Roxadustat.

本文引用的文献

1
Roxadustat and Anemia of Chronic Kidney Disease.罗沙司他与慢性肾脏病贫血
N Engl J Med. 2019 Sep 12;381(11):1070-1072. doi: 10.1056/NEJMe1908978. Epub 2019 Jul 24.
2
Pure red cell aplasia.纯红细胞再生障碍。
Blood. 2016 Nov 24;128(21):2504-2509. doi: 10.1182/blood-2016-05-717140.
3
KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD.KDOQI 美国关于 2012 年 KDIGO 慢性肾脏病贫血临床实践指南的评论。
重组人红细胞生成素治疗伴纯红细胞再生障碍的血液透析患者对环孢素和罗沙司他的阳性反应。
CEN Case Rep. 2024 Dec;13(6):445-449. doi: 10.1007/s13730-024-00865-3. Epub 2024 Mar 25.
4
The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors.慢性肾脏病患者的贫血治疗历程：从促红细胞生成素到缺氧诱导因子脯氨酰羟化酶抑制剂
Clin Kidney J. 2023 Aug 17;16(10):1563-1579. doi: 10.1093/ckj/sfad105. eCollection 2023 Oct.
5
Case Report: Roxadustat in Combination With Rituximab Was Used to Treat EPO-Induced Pure Red Cell Aplasia.病例报告：罗沙司他联合利妥昔单抗用于治疗促红细胞生成素诱导的纯红细胞再生障碍。
Front Nephrol. 2022 Mar 24;2:847847. doi: 10.3389/fneph.2022.847847. eCollection 2022.
6
Effect of roxadustat on red blood cell lifespan in patients with long-term haemodialysis: a single-centre, prospective, single-arm study.罗沙司他对长期血液透析患者红细胞寿命的影响：一项单中心、前瞻性、单臂研究。
Clin Kidney J. 2023 Apr 10;16(9):1500-1507. doi: 10.1093/ckj/sfad080. eCollection 2023 Sep.
7
Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia.缺氧诱导因子脯氨酰羟化酶抑制剂治疗肾性贫血的研究进展
Kidney Dis (Basel). 2022 Oct 31;9(1):1-11. doi: 10.1159/000527835. eCollection 2023 Jan.
8
Case report: Dynamic antibody monitoring in a case of anti-recombinant human erythropoietin-mediated pure red cell aplasia with prolonged course after kidney transplantation.病例报告：肾移植后发生抗重组人促红细胞生成素介导的纯红细胞再生障碍性贫血且病程延长病例中的动态抗体监测
Front Immunol. 2022 Nov 29;13:1049444. doi: 10.3389/fimmu.2022.1049444. eCollection 2022.
Am J Kidney Dis. 2013 Nov;62(5):849-59. doi: 10.1053/j.ajkd.2013.06.008. Epub 2013 Jul 25.
4
Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin.接受促红细胞生成素治疗的患者出现纯红细胞再生障碍和抗促红细胞生成素抗体。
Nephrol Dial Transplant. 2003 Nov;18 Suppl 8:viii37-41. doi: 10.1093/ndt/gfg1091.
5
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.接受重组促红细胞生成素治疗的患者中的纯红细胞再生障碍和抗促红细胞生成素抗体
N Engl J Med. 2002 Feb 14;346(7):469-75. doi: 10.1056/NEJMoa011931.